Interferon-Β lipofection II. Mechanisms involved in cell death and bystander effect induced by cationic lipid-mediated interferon-Β gene transfer to human tumor cells

Cancer Gene Therapy

Volumn 19, Issue 6, 2012, Pages 420-430

  Villaverde, M S ^a   Gil Cardeza, M L ^a   Glikin, G C ^a   Finocchiaro, L M E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Apoptosis; Ewing's sarcoma; interferon b; lipofection; melanoma; reactive oxygen species

Indexed keywords

BETA INTERFERON; PLASMID DNA; REACTIVE OXYGEN METABOLITE; RECOMBINANT BETA INTERFERON;

APOPTOSIS; ARTICLE; BYSTANDER EFFECT; CELL DEATH; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; EWING SARCOMA; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; TRANSGENE;

ANTIOXIDANTS; APOPTOSIS; BYSTANDER EFFECT; CATALASE; CATIONS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; GENE THERAPY; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; LIPOSOMES; MEMBRANE POTENTIAL, MITOCHONDRIAL; NECROSIS; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; SUPEROXIDE DISMUTASE; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861183751     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.19     Document Type: Article

References (38)

1. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 119-134. (Pubitemid 34229387)
2. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992; 84: 1185-1190.
3. Yoshida J, Mizuno M, Wakabayashi T. Interferon-b gene therapy for cancer: basic research to clinical application. Cancer Sci 2004; 95: 858-865. (Pubitemid 40045519)
4. Matsumoto K, Kubo H, Murata H, Uhara H, Takata M, Shibata S et al. A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn J Clin Oncol 2008; 38: 849-856.
5. Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Brocker EB, Neumann C et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer 2002; 86: 179-184. (Pubitemid 34185142)
6. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996; 16: 759-764. (Pubitemid 26389112)
7. Tada H, Maron DJ, Choi EA, Barsoum J, Lei H, Xie Q et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001; 108: 83-95. (Pubitemid 32634925)
8. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852-860.
9. Meyer O, Schughart K, Pavirani A, Kolbe HV. Multiple systemic expression of human interferon-beta in mice can be achieved upon repeated administration of optimized pcTG90-lipoplex. Gene Therapy 2000; 7: 1606-1611.
10. Finocchiaro LME, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Therapy 2008; 15: 267-276. (Pubitemid 351223463)
11. Finocchiaro LME, Villaverde MS, Gil Cardeza ML, Riveros MD, Glikin GC. Cytokineenhanced vaccine and interferon-b plus suicide gene as combined therapy for spontaneous canine sarcomas. Res Vet Sci 2011; 91: 230-234.
12. Chiocca EA, Smith KM, McKinney B, Palmer CA, Rosenfeld S, Lillehei K et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther 2008; 16: 618-626. (Pubitemid 351315003)
13. Wakabayashi T, Natsume A, Hashizume Y, Fujii M, Mizuno M, Yoshida J. A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med 2008; 10: 329-339. (Pubitemid 351517089)
14. Sancëau J, Poupon MF, Delattre O, Sastre-Garau X, Wietzerbin J. Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene 2002; 21: 7700-7709. (Pubitemid 35398816)
15. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160: 328-333. (Pubitemid 28116746)
16. Gil Cardeza ML, Villaverde MS, Fiszman GL, Altamirano NA, Cwirenbaum RA, Glikin GC et al. Suicide gene therapy on spontaneous canine melanoma: correlations between in vivo tumors and their derived multicell spheroids in vitro. Gene Therapy 2010; 17: 26-36.
17. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
18. Brown SV, Hosking P, Li J, Williams N. ATP synthase is responsible for maintaining mitochondrial membrane potential in bloodstream form Trypanosoma brucei. Eukaryot Cell 2006; 5: 45-53. (Pubitemid 43113450)
19. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009; 69: 3918-3926.
20. Cheng JC, Klausen C, Leung PC. Hydrogen peroxide mediates EGF-induced downregulation of E-cadherin expression via p38 MAPK and Snail in human ovarian cancer cells. Mol Endocrinol 2010; 24: 1569-1580.
21. Lejeune D, Hasanuzzaman M, Pitcock A, Francis J, Sehgal I. The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells. Mol Cancer 2006; 5: 21.
22. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Wolff SP. Measurement of plasma hydroperoxide concentration by the ferrous oxidation-xylenol orange assay in conjunction with triphenylphosphine. Anal Biochem 1994; 220: 403-409.
23. L'Haridon F, Besson-Bard A, Binda M, Serrano M, Abou-Mansour E, Balet F et al. A permeable cuticle is associated with the release of reactive oxygen species and induction of innate immunity. PLoS Pathog 2011; 7: e1002148.
24. Kauffman MA, Sterin-Prync A, Papouchado M, Gonzalez E, Vidal AJ, Grossberg SE et al. Immunogenicity of an interferon-beta1a product. Int J Immunopathol Pharmacol 2011; 24: 499-504.
25. Li S, Wilkinson M, Xia X, David M, Xu L, Purkel-Sutton A et al. Induction of IFNregulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol Ther 2005; 11: 112-119. (Pubitemid 40012005)
26. Gilloteaux J, Jamison JM, Arnold D, Neal DR, Summers JL. Morphology and DNA degeneration during autoschizic cell death in bladder carcinoma T24 cells induced by ascorbate and menadione treatment. Anat Rec A Discov Mol Cell Evol Biol 2006; 288: 58-83. (Pubitemid 43062594)
27. Squier MK, Cohen JJ. Standard quantitative assays for apoptosis. Mol Biotechnol 2001; 19: 305-312. (Pubitemid 33063510)
28. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ et al. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol 2002; 22: 3497-3508. (Pubitemid 34453988)
29. Bykov VJ, Lambert JM, Hainaut P, Wiman KG. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle 2009; 8: 2509-2517.
30. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590. (Pubitemid 36385115)
31. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11: 37-51. (Pubitemid 46054520)
32. Wang Y, Blandino G, Oren M, Givol D. Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anticancer drugs. Oncogene 1998; 17: 1923-1930. (Pubitemid 28488460)
33. Zhang XQ, Yang Z, Benedict WF. Direct gene transfer of adenoviral-mediated interferon a into human bladder cancer cells but not the bystander factors produced induces endoplasmic reticulum stress-related cytotoxicity. Cancer Gene Ther 2011; 18: 260-264.
34. Krawiec L, Pizarro R, Aphalo P, Cavanagh E, Pisarev M, Juvenal G et al. Role of peroxidase inhibition by insulin in the bovine thyroid cell proliferation mechanism. Eur J Biochem 2004; 271: 2607-2614. (Pubitemid 38869962)
35. Osawa H, Mizuno M, Hatano M, Nakahara N, Tsuno T, Kuno T et al. Susceptibility to exogenously added interferon-beta protein depends on intracellular interferonbeta mRNA level in human glioma cells. Cytokine 2005; 32: 240-245. (Pubitemid 43144656)
36. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14411-14416. (Pubitemid 28549381)
37. Huang G, Chen Y, Lu H, Cao X. Coupling mitochondrial respiratory chain to cell death: an essential role of mitochondrial complex I in the interferonbeta and retinoic acid-induced cancer cell death. Cell Death Differ 2007; 14: 327-337. (Pubitemid 46092235)
38. Shin-Ya M, Hirai H, Satoh E, Kishida T, Asada H, Aoki F et al. Intracellular interferon triggers Jak/Stat signaling cascade and induces p53-dependent antiviral protection. Biochem Biophys Res Commun 2005; 329: 1139-1146. (Pubitemid 40341393)